Skip to main content

AD: Shocked! The peak value of plasma Aβ42/Aβ40 began to decline 41 years before the deposition of brain Aβ!

 AD: Shocked! The peak value of plasma Aβ42/Aβ40 began to decline 41 years before the deposition of brain Aβ! Alzheimer's diseases: New discovery on plasma Aβ42/Aβ40.  AD: Shocked! The peak value of plasma Aβ42/Aβ40 began to decline 41 years before the deposition of brain Aβ! Amyloid β (Aβ) plaque deposition and phosphorylated tau (p-tau) protein tangles are two important pathological features of Alzheimer's disease (AD), and there are many kinds of AD biomarkers derived around them, Knowledge of the longitudinal trajectories of key markers could not only help improve the selection and monitoring of participants in clinical trials, but also help identify those at high risk for neurodegenerative changes and cognitive impairment.   Although research on AD biomarkers has increased substantially in recent years, research on longitudinal changes in biomarkers is relatively limited. Studies have shown that the levels of plasma Aβ 42 /Aβ 40 , p-tau181 and glial fibrillary acidic...

Malaria mutations: Artemisinin therapy is facing failure in Africa.

 

Malaria mutations: Artemisinin therapy is facing failure in Africa.

Researchers from Juntendo University in Japan published a research paper titled: Evidence of Artemisinin-Resistant Malaria in Africa in the top international medical journal "New England Journal of Medicine" (NEJM).

Image
Malaria mutations: Artemisinin therapy is facing failure in Africa
Malaria mutations: Artemisinin therapy is facing failure in Africa. Researchers from Juntendo University in Japan published a research paper
MEDICAL TREND

Popular posts from this blog

bioRxiv: Scientists have identified a new potential target for the treatment of lung cancer

bioRxiv: Scientists have identified a new potential target for the treatment of lung cancer In cancer research, personalized medicine therapy often uses special genetic changes in a single tumor to find its weakness and attack it. Many tumors carry high levels of mutations, perhaps because of a special antiviral defense Mechanism-APOBEC system, which can accidentally damage DNA and induce mutations. The analysis of cancer mutation characteristics often provides researchers with a large amount of information on the source of mutations, and can guide the use of clinical therapies, including immunotherapy, etc.; in particular, APOBEC3A (A3A, apolipoprotein B mRNA editing enzyme catalyzed polypeptide-like protein 3A, apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3A) has now become the main driver of mutations in cancer cells. Its expression can cause DNA damage and become sensitive to ATR and CHK1 checkpoint kinase inhibitor therapy. Image source: https://www.biorxiv.org/...
Read more

After 70 years of age, language ability declines significantly, and more play and activity can delay it!

After 70 years of age, language ability declines significantly, and more play and activity can delay it!  70~74 years old is a turning point in the decline of language ability Playing more and more active can delay the decline of speech function Liu Chuqun, Professor of Jiangxi Normal University Decreased language fluency is an important speech performance of the elderly.  Studies have found that the age of 70 to 74 is an important turning point for the decline of verbal fluency, but a positive attitude and a healthy lifestyle can delay the decline of the elderly’s verbal fluency to a certain extent. After 70 years of age, language ability declines significantly Most of the elderly, especially the elderly, have these kinds of expressions: words that have no real meaning are repeated back and forth, lack of information to express, the words are inconsistent with what they think and form a verbal error, and the words cannot be remembered by the mouth (tip of tongue phenomenon), ...
Read more

Bispecific CD19/CD20 CAR-T cell therapy: treatment of relapsed or refractory B-cell lymphoma with a complete remission rate of 80%!

Bispecific CD19/CD20 CAR-T cell therapy: treatment of relapsed or refractory B-cell lymphoma with a complete remission rate of 80%! -According to the data of a phase I clinical trial (NCT04007029) announced in the first week of the American Association for Cancer Research (AACR) 2021 annual meeting, bispecific anti-CD19/CD20 CAR-T cell therapy treats relapsed/refractory B Patients with cell lymphoma are well tolerated and show clinical efficacy. Researcher Sanaz Ghafouri, MD, a researcher in hematology and oncology at the University of California, Los Angeles Medical Center, said: “Patients with relapsed/refractory B-cell lymphoma often have more malignant disease trajectories and limited treatment options. Anti-CD19 CAR- T cell therapy has completely changed the treatment of this disease in recent years, but there are still some limitations. Due to the lack of persistence of CAR-T cells and/or the down-regulation of the target antigen CD19 on the tumor, about half of the patients are ...
Read more